Provided is a compound for an organic electric device, an organic electric device using the same, and an electronic device including the organic electric device. Further provided is an organic electric device having high luminous efficiency, low driving voltage, and high heat resistance can be provided, and color purity and lifespan of the organic electric device can be improved.

The present invention describes a method which outlines a process for conversion of CBD to a Δ.sup.9-tetrahydrocannabinol (Δ.sup.9-THC) compound or derivative thereof involving treating a naturally produced CBD intermediate compound with an organoaluminum-based Lewis acid catalyst, under conditions effective to produce the Δ.sup.9-tetrahydrocannabinol compound or derivative thereof at a relatively high concentration. The source of the CBD is from industrial hemp having less than 0.3% Δ.sup.9-THC and extracting and purifying a CBD distillate or isolate or a combination thereof. This procedure will produce Δ.sup.9-THC that is essentially free from any other cannabinoids other than some trace amounts of the initial CBD starting material, or about 95% Δ.sup.9-THC and 2-4% CBD. Another aspect of the present invention relates to a process for further purification and enrichment of the Δ.sup.9-THC using distillation and collecting an essentially pure fraction of Δ.sup.9-THC using additional distillation or enrichment form of purification. Included are methods and processes to scale the reaction from the lab to large scale manufacturing. Included are methods for adding a molecule marker to authenticate high purity Δ.sup.9-THC products. Formulations and uses for pharmaceuticals, nutraceuticals, food products, and topicals are also provided.

Various aspects of this disclosure relate to gas phase methods to decarboxylate cannabinoid carboxylic acids.

Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.

Aspects of the disclosure relate to biosynthesis of cannabinoids and cannabinoid precursors in recombinant cells and in vitro.

A method and system of managing a chain of custody for cannabis is provided that includes depositing one or more identification tags onto the surface of one or more cannabis seeds at a first custodian location, and depositing the identification tags onto the surface of one or more cannabis, wherein the cannabis plants are grown and matured from the cannabis seeds. The method and system further includes receiving the tagged cannabis plants at a second custodian location and extracting cannabinoids from the tagged cannabis plants, wherein the extracted cannabinoids include the one or more identification tags. In addition, the method and system further includes receiving the extracted cannabinoids at a third custodian location, wherein the extracted cannabinoids include the one or more identification tags which may be accumulated from all the prior custodians.

A method and system of managing a chain of custody for cannabis is provided that includes depositing one or more identification tags onto the surface of one or more cannabis seeds at a first custodian location, and depositing the identification tags onto the surface of one or more cannabis, wherein the cannabis plants are grown and matured from the cannabis seeds. The method and system further includes receiving the tagged cannabis plants at a second custodian location and extracting cannabinoids from the tagged cannabis plants, wherein the extracted cannabinoids include the one or more identification tags. In addition, the method and system further includes receiving the extracted cannabinoids at a third custodian location, wherein the extracted cannabinoids include the one or more identification tags which may be accumulated from all the prior custodians.

Described are methods for producing cannabinoid prodrugs as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents for treating diseases.

Described are methods for producing cannabinoid prodrugs as well as methods for formulating such prodrugs in a pharmaceutically acceptable form and their use as therapeutic agents for treating diseases.

A solvent-free method to extract THCA from cannabis, said method comprising: providing a source of THCA-containing cannabis plant; providing a source of natural oil; combining said source of THCA-containing cannabis and said source of natural oil into a blend; milling said blend; optionally, heating the blend during the milling; and extracting a THCA-containing liquid generated during the milling.